Specialty biologics such as Humira (adalimumab), Enbrel, Dupixent, and Stelara list at $2,500 to $9,000 per month in 2026 before any discount. Manufacturers offset that cost for commercially insured patients with copay cards, also called manufacturer coupons or savings cards, that can reduce the patient's share to $0 or $5 per month. Most of these drugs also sit on a plan's highest formulary tier (often Tier 4 or 5, 'specialty') and require prior authorization before the plan will cover a single fill. Two PBM benefit designs, the copay accumulator adjustment program and the copay maximizer program, have emerged specifically to prevent that manufacturer subsidy from also reducing what the health plan pays. Both programs target the same dollar (the manufacturer's copay card payment), but they work through different mechanics and produce different mid-year surprises for patients.
A copay accumulator adjustment program applies the manufacturer's copay card payment to the patient's monthly out-of-pocket cost at the pharmacy counter, exactly as the patient expects, but the plan does not count that manufacturer dollar toward the patient's deductible or annual out-of-pocket maximum. The patient pays little or nothing each month while the card lasts, usually a $10,000 to $20,000 annual maximum. Once the card is exhausted, typically partway through the year, the patient is suddenly responsible for the full remaining deductible and coinsurance, often $2,000 to $7,000 all at once, because none of the prior manufacturer payments applied toward that balance.
PillarRx, SaveOnSP, ScriptSourcing, and Payer Matrix are the four largest copay maximizer vendors operating in 2026. A maximizer identifies drugs with a manufacturer copay card, calculates the card's maximum annual value, and divides that value by 12 to set the patient's official monthly copay at exactly that amount, often $700 to $1,500 per month for a high-cost biologic. The manufacturer card pays that monthly copay in full, so the patient owes $0, but because the health plan classifies the drug as a 'non-essential health benefit' or applies a specialty variable copay tier, none of the manufacturer's money counts toward the deductible either. The distinction from an accumulator: a maximizer is designed from the start to capture the card's entire annual value for the plan's benefit, while an accumulator simply stops crediting once the existing card runs dry.
What Accumulator vs. Maximizer Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same accumulator vs. maximizer can cost many times more at a hospital than at your local pharmacy:
2026 Accumulator vs. Maximizer Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Pharmacy counter, no card, no insurance (cash price, 2026) | $550 - $9,000/month | Full list price for brand biologic; biosimilar cash price runs far lower where available |
| With manufacturer copay card, plan has NO accumulator or maximizer | $0 - $35/month; full card value credits toward deductible | Best-case scenario; increasingly rare for specialty tier drugs in commercial plans |
| With manufacturer copay card, plan runs a copay ACCUMULATOR | $0/month until card limit hit, then $2,000 - $7,000 owed at once | Card payments do not count toward deductible; mid-year bill shock is common |
| With manufacturer copay card, plan runs a copay MAXIMIZER (e.g., SaveOnSP) | $0/month all year, but $0 credits toward deductible for the full year | Copay set to match card's annual maximum divided by 12; patient never sees a bill but never hits their deductible either |
| Medicare Part D (2026) | Plan tier copay/coinsurance until $2,100 annual OOP cap | Manufacturer copay cards are prohibited for Medicare enrollees, so accumulators and maximizers do not apply to Part D |
Accumulator and maximizer rules vary by state and plan. As of January 2026, 26 states plus Washington, D.C. and Puerto Rico restrict one or both practices for at least some drugs; check your plan's Summary of Benefits for the phrase 'accumulator adjustment' or 'variable copay program.'
Source: KFF, Drug Channels, NCSL state legislation tracker, CMS Notice of Benefit and Payment Parameters
Why Hospitals Charge So Much
PBMs and health plans adopted accumulators and maximizers to close what they call the 'manufacturer subsidy loophole.' Before these programs existed, a patient could use a $15,000 annual copay card to pay down their full deductible using entirely manufacturer money, after which the insurer covered 100% of remaining fills with no patient cost-share and no manufacturer money left on the table for the insurer to capture. Insurers argued this let brand manufacturers steer patients away from cheaper generics and biosimilars by making the brand feel free, while the health plan absorbed the full brand-name cost after the deductible was met.
Pharmaceutical manufacturers and patient advocacy groups counter that accumulators and maximizers do not lower total drug spending, they simply shift who pays: the manufacturer's copay card money now subsidizes the insurer's medical loss ratio instead of the patient's deductible, and the patient is left facing a mid-year bill they never budgeted for. The HIV and Hepatitis Policy Institute's 2026 patient survey found accumulator-affected patients were significantly more likely to skip doses or abandon therapy once the card ran out, a pattern also documented by the Crohn's and Colitis Foundation among biologic users for inflammatory bowel disease.
Litigation has reshaped the landscape without fully resolving it. In HIV and Hepatitis Policy Institute et al. v. HHS (D.D.C., September 2023), a federal court struck down the 2021 rule that let insurers decide unilaterally whether to count copay assistance, reverting federal policy to a 2020 standard requiring assistance to count toward cost-sharing for brand drugs without a medically appropriate generic equivalent. As of 2026, the Centers for Medicare & Medicaid Services (cms.gov) has not finalized replacement rulemaking, so enforcement now falls mainly to the 26 states plus Washington, D.C. and Puerto Rico that have passed their own anti-accumulator laws.
Patient Assistance Programs
If your plan applies a copay accumulator or maximizer, the manufacturer copay card stops helping once its annual maximum is spent, and you are left owing full price. Independent, disease-specific charity patient assistance programs (PAPs), funded by manufacturer donations but operated independently, are not subject to accumulator or maximizer rules because they are not tied to a specific brand's copay card. Below are the major independent PAPs used as the fallback in 2026:
Patient assistance programs for Accumulator vs. Maximizer| Manufacturer program | Cost / Benefit | How to apply |
|---|
| PAN Foundation Copay Assistance | Grants up to $12,000/year toward copays; income limit typically 400% - 500% FPL depending on disease fund | panfoundation.org |
| HealthWell Foundation | Copay, premium, and travel grants; income limit 300% - 500% FPL depending on disease fund | healthwellfoundation.org |
| Patient Advocate Foundation Co-Pay Relief | Direct copay grants for chronic and life-threatening conditions; income limit up to 400% FPL | copays.org |
| Good Days | Copay assistance, travel, and premium grants across 40+ disease funds; income limit varies by fund | mygooddays.org |
| NeedyMeds PAP Directory | Free directory of manufacturer PAPs, copay cards, and charity funds by drug name | needymeds.org |
Federal anti-kickback statute (42 U.S.C. Section 1320a-7b) bars manufacturer copay cards for anyone with Medicare, Medicaid, TRICARE, or VA coverage. Independent charity PAPs like the PAN Foundation and HealthWell Foundation can serve Medicare and Medicaid patients because the manufacturer donates to a disease fund rather than paying a specific patient's cost-share directly. Ask your plan whether it applies a copay accumulator or maximizer before assuming a manufacturer copay card alone will get you through the year.
Source: PAN Foundation, HealthWell Foundation, Patient Advocate Foundation, NeedyMeds.org
Medicare Part D
Medicare Part D enrollees are structurally shielded from copay accumulators and maximizers because manufacturer copay cards are illegal for them in the first place. The federal anti-kickback statute prohibits drug manufacturers from offering copay cards to Medicare beneficiaries, so there is no manufacturer subsidy for a plan to accumulate against or maximize in the first place. Part D beneficiaries instead rely on the 2026 annual out-of-pocket cap of $2,100 (set by the Inflation Reduction Act of 2022) and the Part D Low-Income Subsidy, also called Extra Help, which reduces copays to $4.50 to $12.15 for most drugs.
Commercial ACA marketplace plans and employer-sponsored plans are where accumulators and maximizers actually operate, because those plans can legally interact with manufacturer copay cards. The AIDS Institute's February 2026 state grade sheets found that a majority of ACA marketplace plans in several states, including Pennsylvania at 71%, still ran a copay accumulator on at least one specialty drug tier despite mounting state-level restrictions.
Medicaid enrollees face a simpler picture. Medicaid programs already cap prescription copays at $1 to $4 per fill under federal nominal cost-sharing rules, manufacturer copay cards do not apply to Medicaid claims under the anti-kickback statute, and states do not run accumulator or maximizer programs against their own Medicaid formularies.
Common Accumulator vs. Maximizer Billing Errors
Mistakes patients make when their plan applies a copay accumulator or maximizer in 2026:
- Assuming a $0 copay each month means progress toward the deductible. Under both accumulators and maximizers, manufacturer card payments frequently do not count toward the deductible or annual out-of-pocket maximum at all.
- Not reading the plan's Summary of Benefits and Coverage for the phrase 'accumulator adjustment program' or 'variable copay program,' which is how insurers disclose these designs, often in fine print rather than plain language.
- Being surprised by a $2,000 to $7,000 bill mid-year when the manufacturer copay card's annual maximum runs out, without having budgeted for the possibility since the accumulator never credited prior payments.
- Not asking whether a lower-cost biosimilar (for example, an adalimumab biosimilar instead of brand Humira) is exempt from the plan's accumulator under state law, since most state anti-accumulator statutes only protect drugs without a medically appropriate generic or biosimilar equivalent.
- Overlooking independent charity PAPs like the PAN Foundation or HealthWell Foundation as a fallback once a manufacturer card is exhausted, and instead paying full specialty-tier coinsurance out of pocket.
- Confusing the accumulator/maximizer fight over manufacturer coupons with prior authorization denials. A prior authorization denial means the plan will not cover the drug at all regardless of who pays; an accumulator or maximizer only changes whether an already-covered drug's manufacturer coupon counts toward the deductible. Fixing one does not fix the other, and both can hit the same specialty-tier prescription in the same year.
Frequently Asked Questions
What is the difference between a copay accumulator and a copay maximizer?
A copay accumulator lets a manufacturer copay card pay your monthly pharmacy cost as expected, but the plan does not count that manufacturer money toward your deductible, so you owe the full remaining deductible once the card's annual limit runs out mid-year. A copay maximizer, run by vendors like SaveOnSP or PillarRx, calculates the card's full annual value up front and sets your official monthly copay to match it, so the manufacturer effectively pays your entire cost-share for the year but, again, none of it counts toward your deductible. Both leave you no better off on your deductible; the maximizer just avoids the mid-year bill shock.
Is there a biosimilar alternative that avoids the copay accumulator problem?
For adalimumab-based biologics, yes: Cyltezo (Boehringer Ingelheim), Hyrimoz (Sandoz/Novartis), and Hadlima (Samsung Bioepis/Organon) are FDA-approved biosimilars priced 85-90% below brand Humira's list price in 2026. Switching to a biosimilar often removes the accumulator issue entirely because your plan no longer needs a manufacturer card workaround for that drug. Ask your prescriber whether a biosimilar is appropriate before your next refill.
How do I apply for the PAN Foundation or HealthWell Foundation copay assistance program?
Visit panfoundation.org or healthwellfoundation.org and check whether your diagnosis has an open disease fund. Submit an online application with your diagnosis code, insurance information, and household income. Gather proof of income (tax return or pay stubs), proof of insurance, and a prescription confirming your drug. Most complete applications are decided within 24 to 48 hours. Once approved, use your grant ID at the pharmacy going forward until the grant amount or 12-month benefit period is exhausted.
Can I use a manufacturer copay card if I have Medicare?
No. The federal anti-kickback statute (42 U.S.C. Section 1320a-7b) prohibits drug manufacturers from offering copay cards to anyone with Medicare, Medicaid, TRICARE, or VA coverage. This also means Medicare Part D enrollees are not affected by accumulators or maximizers, since there is no manufacturer card for the plan to accumulate against. Medicare beneficiaries should instead rely on the 2026 Part D $2,100 annual out-of-pocket cap and apply for Extra Help (Low-Income Subsidy) through SSA.gov, or apply to an independent charity PAP like PAN Foundation, which is legal for Medicare patients.
What if my insurance applies a copay accumulator or maximizer mid-year without warning?
Request your plan's Summary of Benefits and Coverage language in writing and ask the pharmacy benefit manager for a year-to-date accounting of manufacturer assistance applied to your deductible. File a formal internal appeal citing your state's anti-accumulator law if it applies to your drug and plan type. If the appeal fails, apply immediately to the PAN Foundation or HealthWell Foundation as a fallback, and ask your prescriber about a lower-cost biosimilar alternative that may be exempt from the accumulator under state law.
Does the $2,100 Medicare Part D out-of-pocket cap protect me from accumulators or maximizers?
The 2026 Part D annual out-of-pocket cap of $2,100, set by the Inflation Reduction Act of 2022, protects Medicare beneficiaries from unlimited drug spending, but it is a separate issue from accumulators and maximizers. Since manufacturer copay cards are illegal for Medicare enrollees, accumulators and maximizers are a commercial insurance and ACA marketplace problem, not a Part D problem. If you have Medicare, your protection comes from the $2,100 cap and Extra Help, not from accumulator laws.
What does a specialty biologic cost without insurance in 2026, and how do accumulators change that?
Brand specialty biologics like Humira list at roughly $7,000 to $7,700 for a 30-day supply in 2026, while FDA-approved biosimilars run $550 to $750. Without any manufacturer card, that is the price you pay in cash. With a manufacturer card and no accumulator, your monthly cost can drop to $0-$35 and count toward your deductible. With an accumulator or maximizer, your monthly cost may still be $0, but none of that manufacturer money reduces your deductible, so your true annual liability once the card runs out or the plan year resets is unchanged from the uninsured cash price.
Do I qualify for PAN Foundation or HealthWell Foundation copay assistance?
Eligibility depends on your specific diagnosis fund, but most funds require household income at or below 400% of the federal poverty level in 2026 ($63,840 for one person, $132,000 for a family of four), though some funds use 300% or 500% FPL instead. You also generally need some form of insurance coverage (commercial, Medicare, or Medicaid) with a copay for the specific drug, US residency, and a prescription confirming the qualifying diagnosis. Uninsured patients typically need a manufacturer patient assistance program (PAP) instead, since most copay grant funds assist with an existing copay rather than a full drug cost.
Is a 'copay maximizer' the same thing as the IRA's 'Maximum Fair Price'?
No, and the similar names cause real confusion. A copay maximizer is a commercial PBM benefit-design vendor tool (like SaveOnSP or PillarRx) that maximizes how much of a manufacturer's copay card the health plan captures, and has nothing to do with Medicare. The Maximum Fair Price is the price Medicare itself negotiated under the Inflation Reduction Act of 2022 for 10 Round-1 drugs (Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and Fiasp/NovoLog), effective January 1, 2026. Copay accumulators and maximizers apply to commercial insurance and ACA marketplace plans; the Maximum Fair Price applies only to Medicare Part D.
